Confirming Target Engagement for Reversible Inhibitors In Vivo by Kinetically Tuned Activity-Based Probes

Alexander Adibekian[†,§,1], **Brent R. Martin**[†,§,2], **Jae Won Chang**[†], **Ku-Lung Hsu**[†], **Katsunori Tsuboi**[†], **Daniel A. Bachovchin**[†], **Anna E. Speers**[†], **Steven J. Brown**[‡], **Timothy Spicer**[‡], **Virneliz Fernandez-Vega**[‡], **Jill Ferguson**[‡], **Peter S. Hodder**[‡,T], **Hugh Rosen**[†,#], and **Benjamin F. Cravatt**[†,*]

[†]The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037 Lead Identification Division

[‡]Molecular Screening Center, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458

[T]Department of Molecular Therapeutics, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458

[#]The Scripps Research Institute Molecular Screening Center, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037

Abstract

The development of small-molecule inhibitors for perturbing enzyme function requires assays to confirm that the inhibitors interact with their enzymatic targets *in vivo*. Determining target engagement *in vivo* can be particularly challenging for poorly characterized enzymes that lack known biomarkers (e.g., endogenous substrates and products) to report on their inhibition. Here, we describe a competitive activity-based protein profiling (ABPP) method for measuring the binding of reversible inhibitors to enzymes in animal models. Key to the success of this approach is the use of activity-based probes that show tempered rates of reactivity with enzymes, such that competition for target engagement with reversible inhibitors can be measured *in vivo*. We apply the competitive ABPP strategy to evaluate a newly described class of piperazine amide reversible inhibitors for the serine hydrolases LYPAL1 and LYPLA2, two enzymes for which selective, *in vivo*-active inhibitors are lacking. Competitive ABPP identified individual piperazine amides that selectively inhibit LYPLA1 or LYPLA2 in mice. In summary, competitive ABPP adapted to operate with moderately reactive probes can assess the target engagement of reversible inhibitors in animal models to facilitate the discovery of small-molecule probes for characterizing enzyme function *in vivo*.

Enzyme inhibitors are valuable chemical probes to perturb biochemical pathways in living systems and, where appropriate, can be developed into new medicines to treat human disease. Most enzymes in the human proteome, however, still lack selective inhibitors[1].

Corresponding Author: cravatt@scripps.edu.
§**Author Contributions**
These authors contributed equally.
[1]Department of Biochemistry, University of Geneva, Sciences II, 30 Quai Ernest-Ansermet, 1211 Geneva 4, Switzerland
[2]Department of Chemistry, University of Michigan, 930, North University Avenue, Ann Arbor, Michigan 48109, USA

While advances in high-throughput screening[2] combined with chemoproteomic platforms[1] have begun to accelerate the development of enzyme inhibitors with excellent potency and selectivity, it is often challenging to determine whether these inhibitors interact with their targets in living systems, especially for poorly characterized enzymes that lack endogenous substrate/product biomarkers.

We, and others have previously shown that activity-based protein profiling (ABPP), a chemoproteomic method that uses active site-directed, covalent probes to evaluate enzyme function in native biological systems,[3] can determine target engagement for enzyme inhibitors in cell and animal models.[4–7] But, so far, this approach has been limited to assessing irreversible inhibitors for multiple reasons. First, many activity-based probes show poor bioavailablity *in vivo*, which restricts their utility to the *ex vivo* analysis of tissue proteomes from inhibitor-treated animals, an assay protocol that involves considerable sample processing and dilution that can compromise the detection of reversible inhibitor-enzyme interactions. Second, even for activity-based probes that show suitable bioavailability, managing their rate of reactivity *in vivo* is difficult, which, if not properly controlled, can result in the probes "outcompeting" reversible inhibitors and failing to record their target interactions. Here, we sought to address these challenges by creating kinetically tuned activity-based probes that enable direct competitive profiling of reversible inhibitors *in vivo*. We applied this strategy to assess newly described inhibitors for the serine hydrolases lysophospholipase 1 (LYPLA1) and lysophospholipase 2 (LYPLA2), enzymes that, to date, have lacked selective and *in vivo*-active inhibitors.

LYPLA1 and LYPLA2 were initially characterized as phospholipases based on in vitro substrate assays.[8–9] LYPLA1 has since been found to also act as protein palmitoyl thioesterase (PPT) that removes palmitate modifications from cysteine residues on proteins, such as the Ras GTPases.[10] LYPLA2 shares 65% sequence identity with LYPLA1, but its role as a PPT remains unknown. While considerable biochemical and cellular data support a role for LYPLA1 as a PPT,[11–13] little is known about the functions of LYPLA1 and LYPLA2 *in vivo*. Several inhibitors of LYPLA1 have been described,[11,14] but none of these agents have been demonstrated to selectively inhibit LYPLA1 over LYPLA2, nor have they been shown to inhibit LYPLA1 in animal models. This latter goal is further challenged by a lack of robust substrate/product biomarkers that can be used to confirm LYPLA1/2 inhibition *in vivo*.

To identify new classes of LYPLA1 and LYPLA2 inhibitors we first established enzyme assays compatible with high-throughput screening. As serine hydrolases, LYPLA1 and LYPLA2 react with fluorophosphonate (FP) activity-based probes and can therefore be assayed by a recently described, high-throughput screening (HTS)-compatible competitive ABPP platform that measures the reactivity of fluorophore-conjugated FP probes with serine hydrolases by fluorescence polarization (fluopol).[15] In fluopol-ABPP, small-molecules compete with FP-probes for binding to serine hydrolases and are recorded as hits by their ability to reduce fluopol signal. We expressed and purified human LYPLA1 and LYPLA2 enzymes and confirmed that the wild-type, but not the catalytically dead serine mutants (S119A and S112A, respectively) reacted with a rhodamine-conjugated FP probe (FP-Rh) to generate time-dependent increases in fluopol signal (Figure 1). In collaboration with the Molecular Libraries Production Centers Network (MLCPN), we then screened 315,004 compounds for LYPLA1 or LYPLA2 inhibition. Compounds were classified as potential hits if they produced a >30% reduction of fluopol signal (Figure S1). Following a confirmation screen, 331 and 790 compounds were found to inhibit LYPLA1 and LYPLA2, respectively. We then manually filtered these compounds for those with the highest inhibition and removed non-selective compounds identified as hits in previous fluopol-ABPP screens of other serine hydrolases (PME1 and RBBP9).

The remaining 91 LYPLA1, 61 LYPLA2, and 95 dual LYPLA1/LYPLA2 inhibitors were analyzed by gel-based ABPP in HEK293T cell proteomes, which express high endogenous levels of LYPLA1 and LYPLA2. We established assay parameters compatible with assessing both reversible and irreversible inhibitors by using a pegylated FP-Rh probe (FP-peg-Rh), which reacts more slowly with LYPLA1 and LYPLA2 compared to the FP-Rh probe to produce only partial enzyme labeling under the reaction conditions employed for inhibitor evaluation (Figure S2). From this analysis, a diverse set of piperazine amides emerged as attractive inhibitors for LYPLA1 and LYPLA2. The *p*-methoxyphenyl piperazine amide **1**, for instance, completely inhibited LYPLA2 when tested at 1 uM, while showing no inhibition of LYPLA1 or other serine hydrolases detected in the HEK293T proteome (Figure 2A–C). A complementary profile was observed for the 2-furoyl piperazine amide **21**, which produced near-complete inhibition of LYPLA1 without showing any cross-reactivity with LYPLA2 or other serine hydrolases (Figure 2A–C).

To better understand the structure-activity relationship (SAR) of **1** and **21**, we purchased and tested the related compounds **2-13** and **22-33** (Figure 2A and 2B). Compounds **7**, **9**, and **10**, all bearing para-substituted phenyl groups, inhibited LYPLA2 by 70–90%, while ortho-, meta- or unsubstituted aryl piperazines did not exhibit inhibitory activity at 1 µM. Both the 2-furoyl piperazine and 2,5-substituted anilide groups of **21** were required for maximal and selective inhibition of LYPLA1, as revealed by the profiles of disubstituted anilides **28**-**30**, which showed moderate cross-inhibition of LYPLA2 (50–70 % at the concentration of 1 µM), and the structurally related amide **26**, which did not inhibit LYPLA1 or LYPLA2. We resynthesized **1** and **21** as described in the Supplementary Methods and confirmed their structural assignment and inhibitory activity by ^{1}H-NMR and competitive ABPP assays, respectively (Figure S3).

Neither **1** nor **21** possess any obvious electrophilic groups for reaction with LYPLA1 or LYPLA2, which led us to conclude that they were likely acting as reversible inhibitors. We confirmed the reversibility of enzyme inhibition for **1** and **21** by gel filtration experiments, which showed complete recovery of FP-peg-Rh labeling of LYPLA1 and LYPLA2 after two consecutive gel filtrations (Figure 2D). In contrast, no recovery of FP-peg-Rh labeling was observed for the 1,2,3-triazole urea irreversible inhibitor AA26-9,[7] even after three gel filtration events (Figure 2D).[16] **1** and **21** showed good potency for LYPLA2 and LYPLA1 with IC_{50} values of 144 and 210 nM, respectively, derived from gel-based competitive ABPP assays (Figure 2C, Figure S5) and K_i values of 230 and 300 nM, respectively, derived from a fluorogenic substrate assay using purified enzymes. (Figure 2E, Figure S6). We further verified the activity and selectivity of **1** and **21** using the LC-MS platform ABPP-SILAC[4,7], which revealed >95% inhibition of LYPLA2 and LYPLA1, respectively, without any changes in the activity of ~25 other serine hydrolases detected in the mouse BW5147 T-cell hybridoma proteome (Figure S7 and Table S1).

We next asked whether **1** and **21** could also inhibit LYPLA2 and LYPLA1 in living cells. As mentioned previously, it is not straightforward to answer this question for reversible inhibitors using standard competitive ABPP protocols, which involve incubation of living cells with an inhibitor followed by *ex vivo* treatment of cell lysates with an activity-based probe. While, in principle, we could perform competitive ABPP *in situ* using alkynylated FP probes,[17] we were concerned that the high rates of reactivity displayed by FP probes with most serine hydrolases would complicate the analysis of reversible inhibitors. Consistent with this premise, we found that LYPLA1, LYPLA2, and several other serine hydrolases were rapidly inactivated (within 5 min) by an FP-alkyne probe **34** (Figure 3A, Figure S8). We hypothesized that implementing an alternative probe with more tempered reactivity could facilitate competitive ABPP *in situ* under kinetically controlled conditions. We tested probe **35**, which is based on a recently discovered triazole urea scaffold for serine hydrolase

inhibitors,[7] and found that it reacted much more slowly than FP-alkyne with LYPLA1, LYPLA2, and most serine hydrolases (Figure 3A, Figure S8). We next incubated HEK293T and mouse T cells with **1** and **21** (5 μM) or DMSO for 3 hours followed by a 1 hr treatment with probe **35** (50 μM). Cells were harvested, lysed, and probe-labeled enzymes visualized by click chemistry[18,19] conjugation with a Rh-azide reporter tag.[20] Gel-based ABPP revealed the selective and near-complete (>95%) inhibition of LYPLA2 and LYPLA1 in cells treated with **1** and **21**, respectively (Figure 3B, Figure S9). The *in situ* activity of both inhibitors was further confirmed by ABPP-SILAC, which revealed selective inhibition of LYPLA2 and LYPLA1 by **1** and **21**, respectively, across the 15+ serine hydrolases detected in this analysis (Figure 3C, Table S1, and Figure S10).

We finally asked whether competitive ABPP with probe **35** could also be used to determine the inhibition of LYPLA1 and LYPLA2 *in vivo*. Mice were administered **1** and **21** (each at 50 mg/kg in PEG300, i.p.) or vehicle and, after 3 hr, treated with probe **35** (100 mg/kg in PEG300, i.p.) for 1 hr. Mice were then sacrificed and their tissues removed, processed, reacted with Rh-azide, and analyzed by gel-based ABPP. The gel profiles confirmed that **1** and **21** selectively and near-completely (>90%) inhibited LYPLA2 and LYPLA1, respectively, in lung, heart, and kidney (Figure 4). In contrast, only partial blockade (~50%) was observed for LYPLA1 and LYPLA2 in brain, suggesting limited CNS penetration for the inhibitors. No detectable inhibition of LYPLA1 or LYPLA2 was observed in liver, perhaps reflecting rapid metabolism of **1** and **21** in this organ. These data indicate that competitive ABPP can quantitatively assess target engagement *in vivo* across numerous organs in parallel to reveal cases of tissue-restricted inhibition.

In summary, we have described herein an advanced strategy for competitive ABPP that uses kinetically tuned probes to determine target engagement for reversible inhibitors in living cells and mice. We applied this approach to identify and evaluate acyl piperidines **1** and **21** as, to our knowledge, the first selective and *in vivo*-active inhibitors for serine hydrolases LYPLA2 and LYPLA1, respectively. We anticipate that future application of **1** and **21** in conjunction with global methods to assess protein palmitoylation [17,21] and lipid metabolites,[22] respectively, should help to define the endogenous functions of LYPLA1/2. The information on target engagement provided by competitive ABPP should help to guide these studies by distinguishing tissues where maximal enzyme inhibition was achieved by **1** and **21** (e.g., heart, lung, kidney) from those where enzyme blockade was incomplete (brain) or absent (liver). Projecting forward, we believe that the strategy described herein should also be applicable to characterize reversible inhibitors for additional serine hydrolases and other classes of enzymes for which activity-based probes have been developed.[3] One limitation that we should mention, however, is that kinetically tuned activity-based probes may sacrifice some of the breadth of proteomic coverage provided by more broadly reactive probes, which is especially pertinent to large enzyme classes like the serine hydrolases.[23] It is also not clear, in many instances, why certain probes show greater or lesser rates of reactivity with individual enzymes, which means that identifying a matched probe is still largely an empirical process. Nonetheless, we anticipate that these issues can be addressed by synthesizing and screening a suite of probes to identify reagents that are tailored to profile complementary subsets of serine hydrolases such that most of these enzymes can be evaluated for reversible inhibition across a wide range of biological systems.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Moellering RE, Cravatt BF. Chem Biol. 2012; 19:11. [PubMed: 22284350]

2. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, Auld DS. Nat Chem Biol. 2007; 3:466. [PubMed: 17637779]

3. Cravatt BF, Wright AT, Kozarich JW. Annu Rev Biochem. 2008; 77:383. [PubMed: 18366325]

4. Deu E, Verdoes M, Bogyo M. Nat Struct Mol Biol. 2012; 19:9. [PubMed: 22218294]

5. Long JZ, Nomura DK, Cravatt BF. Chem Biol. 2009; 16:744. [PubMed: 19635411]

6. Chang JW, Nomura DK, Cravatt BF. Chem Biol. 2011; 18:476. [PubMed: 21513884]

7. Adibekian A, Martin BR, Wang C, Hsu KL, Bachovchin DA, Niessen S, Hoover H, Cravatt BF. Nat Chem Biol. 2011; 7:469. [PubMed: 21572424]

8. Sugimoto H, Hayashi H, Yamashita S. Journal of Biological Chemistry. 1996; 271:7705. [PubMed: 8631810]

9. Toyoda T, Sugimoto H, Yamashita S. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1999; 1437:182.

10. Duncan JA, Gilman AG. J Biol Chem. 1998; 273:15830. [PubMed: 9624183]

11. Dekker FJ, Rocks O, Vartak N, Menninger S, Hedberg C, Balamurugan R, Wetzel S, Renner S, Gerauer M, Scholermann B, Rusch M, Kramer JW, Rauh D, Coates GW, Brunsveld L, Bastiaens PI, Waldmann H. Nat Chem Biol. 2010; 6:449. [PubMed: 20418879]

12. Duncan JA, Gilman AG. J Biol Chem. 2002; 277:31740. [PubMed: 12080046]

13. Yeh DC, Duncan JA, Yamashita S, Michel T. Journal of Biological Chemistry. 1999; 274:33148. [PubMed: 10551886]

14. Biel M, Deck P, Giannis A, Waldmann H. Chemistry – A European Journal. 2006; 12:4121.

15. Bachovchin DA, Brown SJ, Rosen H, Cravatt BF. Nat Biotechnol. 2009; 27:387. [PubMed: 19329999]

16. Consistent with a reversible mechanism of inhibition, both **1** and **21** showed greatly attenuated apparent inhibitory activity in competitive ABPP reactions performed with the FP-Rh probe, which reacts much more rapidly with LYPLA1 and LYPLA2 compared to the FP-peg-Rh probe. In contrast, the irreversible inhibitor AA26-9 showed equivalent activity when tested with either FP-Rh or FP-peg-Rh probes (Figure S4).

17. Martin BR, Wang C, Adibekian A, Tully SE, Cravatt BF. Nat Methods. 2012; 9:84. [PubMed: 22056678]

18. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. Angew Chem Int Ed Engl. 2002; 41:2002.

19. Tornoe CW, Christensen C, Meldal M. J Org Chem. 2002; 67:3057. [PubMed: 11975567]

20. Speers AE, Cravatt BF. Chem Biol. 2004; 11:535. [PubMed: 15123248]

21. Martin BR, Cravatt BF. Nat Methods. 2009; 6:135. [PubMed: 19137006]

22. Gross RW, Han X. Chem Biol. 2011; 18:284. [PubMed: 21439472]

23. Long JZ, Cravatt BF. Chem Rev. 2011; 111:6022. [PubMed: 21696217]

Figure 1.
A fluopol-ABPP assay to screen for LYPLA1 and LYPLA2 inhibitors. Time course of FP-Rh labeling for LYPLA1 and LYPLA2 as determined by fluopol-ABPP. No fluopol increase was observed in the absence of enzymes or with the S119A LYPLA1 and S122A LYPLA2 catalytic mutants.

Figure 2.
Identification of acyl piperidines **1** and **21** as potent and selective reversible inhibitors of LYPLA2 and LYPLA1, respectively. (A) Gel-based competitive ABPP of HTS hits **1** and **21** and structurally related compounds **2**-**13** and **22**-**33** tested in a HEK293T proteome. (B) Structures of profiled compounds. (C) Concentration-dependent blockade of FP-peg-Rh labeling of LYPLA2 and LYPLA1 by **1** and **21**, respectively, in a HEK 293T proteome. Fluorescent gels shown in grayscale are representative of at least three independent experiments. (D) Competitive ABPP analysis of gel filtration experiments to determine the reversibility of LYPLA2 and LYPLA1 inhibition by **1** and **21**; also shown is the profile for the irreversible inhibitor 1,2,3-triazole urea **AA26-9**. (E) Kinetic values for inhibition of recombinant human LYPLA2 and LYPLA1 by **1** and **21**, respectively, determined using a fluorescent substrate assay. Data represent means ± s.d. ($n = 4$).

Figure 3.
Competitive ABPP of **1** and **21** in living cells. (A) Time-dependent competition of FP-Rh
labeling by the click-able probes FP-alkyne **34** and triazole urea **35** in a mouse brain
membrane proteome. (B) Gel-based competitive ABPP of HEK293T cells treated with **1** and
21 (5 μM, 3 h) following by probe **35** (50 μM, 1 h) to measure *in situ* target engagement.
(C) ABPP-SILAC analysis of serine hydrolase activities from inhibitor-treated HEK 293T
cells. Bars represent means ± s.d. of light/heavy ratios for the multiple peptides observed for
each enzyme; data are derived from two independent biological replicates.

Figure 4.
Evaluating target engagement for **1** and **21** *in vivo*. (A) General layout of a competitive ABPP experiment to measure target engagement for reversible inhibitors in mice. (B) Competitive ABPP gels of tissue proteomes from mice treated with **1** and **21** (50 mg/kg, 3 hr) followed by probe **35** (100 mg/kg, 1 hr) ; $n = 3$ mice/group.